









Markets
/
Stocks
/
nasdaq-rlay
/

Relay Therapeutics Inc

RLAY



View Detailed Chart

8.560USD

-0.090-1.04%

Close 12/26, 16:00（ET）Quotes delayed by 15 min

1.48BMarket Cap

LossP/E TTM



Relay Therapeutics Inc

8.560

-0.090-1.04%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.04%

5 Days

+1.90%

1 Month

+6.60%

6 Months

+157.83%

Year to Date

+107.77%

1 Year

+92.36%

View Detailed Chart

TradingKey Stock Score of Relay Therapeutics Inc

Currency: USD Updated: 2025-12-26

Key Insights

Relay Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 56/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.90.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Relay Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

56 / 404

Overall Ranking

146 / 4563

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 12 analysts

Buy

Current Rating

13.900

Target Price

+82.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Relay Therapeutics Inc Highlights

StrengthsRisks

Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 624.62% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.01M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 10.01M.

Undervalued

The company’s latest PE is -4.99, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 168.31M shares, decreasing 18.46% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 9.37M shares of this stock.